Bovi-Shield GOLD 3 (Canada)

Manufacturer: Pfizer

Bovine Rhinotracheitis-virus Diarrhea-parainfluenza-3 Vaccine

Modified Live Virus

Product Description

Bovi-Shield GOLD 3 is for vaccination of healthy cattle as an aid in preventing infectious bovine rhinotracheitis caused by infectious bovine rhinotracheitis (IBR) virus, bovine viral diarrhea caused by bovine virus diarrhea (BVD) virus Types 1 and 2, and disease caused by parainfluenza-3 (PI-3) virus. Bovi-Shield GOLD 3 may be administered to pregnant cattle provided they were vaccinated, according to label directions, with Bovi-Shield FP™ 4+L5, Bovi-Shield FP 4+VL5, Bovi-Shield GOLD FP 5 L5, Bovi-Shield GOLD FP 5 VL5, PregGuard^® FP 9 or PregGuard GOLD FP 10 within the past 12 months. Bovi-Shield GOLD 3 may also be administered to calves nursing pregnant cows provided their dams were vaccinated within the past 12 months as described above. Bovi-Shield GOLD 3 is a freeze-dried preparation of modified live virus (MLV) strains of IBR, BVD (Types 1 and 2), and PI-3 viruses, plus a sterile diluent used to rehydrate the freeze-dried vaccine. Viral antigens are propagated in established cell lines.

Disease Description

IBR, BVD, and PI-3 viruses are commonly associated with respiratory disease and/or reproductive failure in cattle. IBR virus infection is characterized by high temperature, excessive nasal discharge, conjunctivitis and ocular discharge, inflamed nose (“red nose”), increased rate of respiration, coughing, loss of appetite, and depression. Cattle infected during pregnancy may abort.

BVD virus may be transmitted in nasal secretions, saliva, blood, feces, and/or urine, and by direct contact with contaminated objects; it invades through the nose and mouth and replicates systemically. Infection during pregnancy may result in abortion, fetal resorption, or congenital malformation of the fetus. Moreover, if susceptible cows are infected with noncytopathic BVD virus during the first trimester of pregnancy, their calves may be born persistently infected with the virus. Exposure of those calves to certain virulent cytopathic BVD virus strains may precipitate BVD-mucosal disease. Both BVD Types 1 and 2 can show a variety of clinical signs. The signs may be mild and not readily apparent. Clinical signs may include severe immune suppression, diarrhea, anorexia, depression, fever and respiratory disease. If infected with some Type 2 strains of BVD, severe thrombocytopenia may occur and hemorrhaging may be seen.

PI-3 virus usually localizes in the upper respiratory tract, causing elevated temperature and moderate nasal and ocular discharge. Although clinical signs typically are mild, PI-3 infection weakens respiratory tissues. Invasion and replication of other pathogens, particularly Pasteurella spp., is thereby facilitated and may result in pneumonia.

Safety And Efficacy

The cell lines on which the modified live virus fractions are produced have been extensively tested to ensure freedom from adventitious agents. Two studies were conducted demonstrating the safety of the BVD Type 2 fraction of Bovi-Shield GOLD 3. In the first study 14- to 15-month-old crossbred beef calves negative for BVD virus and BVD neutralizing antibodies, and with no history of BVD vaccination, were given a field dose of the BVD Type 2 strain intramuscularly. Susceptible contact control animals maintained in this study did not seroconvert to BVD. In the second study, 4- to 8-week-old, colostrum-deprived crossbred beef calves, negative for BVD virus and BVD neutralizing antibodies, were given a field dose of the BVD Type 2 strain intranasally. In both studies, no clinical signs attributable to BVD infection were observed and attempts to re-isolate the vaccine virus from nasal secretions were unsuccessful.

The safety of the fractions of Bovi-Shield GOLD 3 was demonstrated in 3 field safety studies, each at different geographic locations, utilizing a total of 605 animals. Safety was evaluated in 6- to 8-month-old beef calves in a feedlot environment, in 3- to 7-month-old beef calves prior to weaning, and in 1- to 4-week-old dairy calves. No injection site, serious systemic or allergic reactions or clinical abnormalities attributable to vaccination were observed.

Three field studies demonstrated the safety of Bovi-Shield GOLD 3 when administered to pregnant cows previously vaccinated with one of the Bovi-Shield FP or PregGuard FP products. In all three studies, cows were vaccinated with either Bovi-Shield FP 4+L5 or PregGuard FP 9 between 12 and 17 months prior to vaccination with either Bovi-Shield GOLD FP 5 VL5 or placebo during the first, second, or third trimester of pregnancy. The pregnancy status of cows vaccinated during the first trimester of pregnancy was determined approximately 3 months postvaccination. Pregnancy was confirmed in 197 of 198 (99.5%) placebo-vaccinated cows and 198 of 200 (99%) cows vaccinated with Bovi-Shield GOLD FP 5 VL5.

Cows vaccinated during the second or third trimester of pregnancy were observed through calving, and the health status of their newborn calves was determined. Second trimester vaccination resulted in the delivery of healthy calves in 149 of 150 (99.3%) placebo vaccinates, and in 162 of 164 (98.8%) cows vaccinated with Bovi-Shield GOLD FP 5 VL5. One hundred percent of cows vaccinated with placebo (138 of 138) and Bovi-Shield (184 of 184) during the third trimester of pregnancy delivered healthy calves.

Efficacy of each fraction of Bovi-Shield GOLD 3 was demonstrated in challenge-of-immunity studies. Cattle vaccinated with any fraction of Bovi-Shield GOLD 3, followed by challenge with a disease-causing strain of that fraction, showed no signs or had significantly fewer clinical signs than nonvaccinated control cattle. Serologic studies demonstrated no immunologic interference among the fractions of Bovi-Shield GOLD 3.

The effectiveness of Bovi-Shield GOLD 3 in providing protection from a virulent BVDV Type 2 challenge was demonstrated in 3- to 4-month-old, colostrum-deprived beef calves. Vaccinated calves, along with a group of nonvaccinated controls, were challenged intranasally with virulent, noncytopathic BVDV Type 2 at 28 days postvaccination. Results are summarized in the following table:

Group	No. Of Calves	% Viremic	% Morbidity*	% Mortality
Controls	10	100a	100a	70a
Bovi-Shield GOLD 5	20	5b	10b	0b

*Observed ill for ≥ 1 day.

^a,bNumbers within the same column with different lower-case superscripts are significantly different (P ≤ 0.05).

This study demonstrated that vaccination with Bovi-Shield GOLD 3, containing immunogenicity levels of BVD Types 1 and 2, was effective in protecting young calves from severe BVD Type 2 disease as evidenced by significant differences between vaccinates and controls in mortality, morbidity, viremia, rectal temperatures, white blood cell counts, and platelet counts.

Directions

1. General Directions: Vaccination of healthy cattle is recommended. Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided, shake well, and administer 2 mL intramuscularly. In accordance with Beef Quality Assurance guidelines, this product should be administered in the muscular region of the neck.

2. Primary Vaccination: Administer a single 2-mL dose to healthy cattle.

3. Revaccination: Annual revaccination with a single dose is recommended.

4. Good animal husbandry and herd health management practices should be employed.

Precautions

1. Do not use in pregnant cows (abortions can result) unless they were vaccinated, according to label directions, with Bovi-Shield FP 4+L5, Bovi-Shield FP 4+VL5, Bovi-Shield GOLD FP 5 L5, Bovi-Shield GOLD FP 5 VL5, PregGuard FP 9 or PregGuard GOLD FP 10 within the past 12 months. Do not use in calves nursing pregnant cows unless their dams were vaccinated within the past 12 months as described above.

2. Store at 2°-7°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.

3. Use entire contents when first opened.

4. Sterilized syringes and needles should be used to administer this vaccine. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine.

5. Burn containers and all unused contents.

6. Do not vaccinate within 21 days before slaughter.

7. Contains gentamicin as preservative.

8. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.

9. This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.

Technical inquiries should be directed to Pfizer Animal Health Technical Services, (800) 461-0917.

^®Registered trade-mark of Pfizer Products Inc.; Pfizer Canada Inc. licensee

™Trade-mark of Pfizer Products Inc.; Pfizer Canada Inc. licensee

For veterinary use only

U.S. Veterinary License No. 189

Pfizer Animal Health, Exton, PA 19341, USA, Div. of Pfizer Inc, NY, NY 10017

75-0757-00

Presentation

10 and 50 dose vials.

Nac No.

11983230